GCCL(Global Clinical Central Lab)

What GCCL(Global Clinical Central Lab) does

GCCL Co., Ltd. (Global Clinical Central Lab), founded in 2019 as a spin-off of the Green Cross Medical Foundation's clinical trial analysis division, is a South Korea-headquartered provider of integrated clinical trial sample analysis services and a majority-owned subsidiary of GC Cell (65.45% stake), part of the GC Group with a 60-year operating history. The company operates from Yongin, Gyeonggi-do, and claims the No.1 position in Korea's central lab CRO market with 200+ global partners as of 2025, having handled more than 30% of Korea's COVID-19 vaccine and therapeutic sample analysis during the pandemic.

GCCL delivers a GCLP-certified one-stop lab platform combining Central Laboratory, Bioanalytical Laboratory, and BSL-3 biosafety capabilities under a single integrated system. Core technology includes the proprietary G-Hub specimen management platform with real-time temperature monitoring, barcode-based traceability, and an AI-powered SOP search function, alongside Watson LIMS for global regulatory compliance. The analytical portfolio spans five platform technologies — LBA (ELISA, MSD, Luminex, ECL), FACS (BD Lyric), PCR/ddPCR, LC-MS/MS, and ELISpot — supporting over 5,000 test items across PK/PD, biomarker, immunogenicity (ADA/NAb), and safety analysis. Therapeutic specializations include oncology (39% of biopharma sample analysis, with 72% immuno-oncology share), cell and gene therapy (including Korea's first approved CAR-T therapy RIMQARTO), CNS disorders, and infectious disease/vaccines.

GCCL generates revenue through project-based professional services fees across four streams: Central Laboratory Services, Bioanalytical Services, Sample Management and Logistics, and Clinical Support Services. Pricing is customized per project based on trial parameters (subjects, visits, test items, logistics requirements, project phase) with multi-year contracts. The company distributes services through direct enterprise sales, over 50 directly managed domestic branches for Korean sample collection, global logistics partners, and channel partnerships with MICS and OPIS for European/American client access. Go-to-market emphasizes industry conference participation (BIO, ASCO, ESMO, World Vaccine Congress) and partnering platforms. The customer base consists primarily of pharmaceutical and biotech companies, with additional engagement through global CROs and government-backed research institutions.

Name

GCCL(Global Clinical Central Lab)

Legal name

GCCL Co., Ltd.

Website

https://eng.gccl.co.kr

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

GCCL is Korea's leading GCLP-certified central lab CRO, providing integrated clinical trial sample analysis spanning central lab, bioanalytical, and BSL-3 services for global pharmaceutical and biotech companies across PK/PD, biomarker, immunogenicity, and vaccine analytics.

Ownership category

akta.pro rank

Product category

Clinical Trial Central Laboratory Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Clinical trial sample analysis
• Central laboratory services
• Bioanalytical testing
• Pharmacokinetic biomarker analysis
• Clinical research organization

Headquarters

HQ city

Yongin-si

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Central Laboratory Services: GCCL provides diagnostic tests, medical examinations, and pathological tests required for clinical trials, covering safety and efficacy analysis across over 5,000 test items from general tests to specialized molecular genetic tests. Revenue is generated through project-based service fees charged to pharma and biotech sponsors.
2. Bioanalytical Services: Method development and validation, PK/PD analysis, biomarker analysis, immunogenicity testing (ADA, NAb), and biomarker discovery for early and late clinical trial phases. Revenue is earned through assay development fees and per-sample analysis charges.
3. Sample Management & Logistics: PBMC isolation, sample preparation, sample storage (biobank with RMS at various temperatures), and bio logistics including transport and real-time tracking. Revenue generated through sample processing and storage fees.
4. Clinical Support Services: Project management, research support, clinical consulting including PK analysis consulting and method development/validation services. Revenue through project management fees and consulting engagements.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels14 records

Core offering

GCCL provides integrated clinical trial sample analysis services combining Central Lab, Bioanalytical Lab, and Clinical Support under one GCLP-certified platform. The company delivers diagnostic, medical, pathological, and molecular genetic tests spanning over 5,000 safety and efficacy items, alongside PK/PD analysis, biomarker analysis, immunogenicity testing (ADA/NAb), sample management, and project-based lab kit production for global pharmaceutical and biotech sponsors across Phase I–IV clinical trials.

Product overview

GCCL provides an integrated one-stop lab solution for clinical trial sample analysis, combining Central Lab, Bioanalytical Lab, and R&D services under a single system. The portfolio is organized around three core divisions: (1) Central Lab Services covering safety testing, sample management, and biobanking with multi-temperature preservation; (2) Bioanalytical Laboratory Services utilizing multiple analytical platforms (LBA, FACS, PCR, LC-MS/MS, ELISpot); and (3) Clinical Support Services including project management and data management. The company specializes in key therapeutic areas including oncology, cell & gene therapy, CNS disorders, and infectious diseases/vaccines. Services span the entire clinical trial lifecycle from Phase I to Phase IV, with capabilities in PK/PD analysis, biomarker discovery, immunogenicity testing (ADA/NAb), and custom assay development. Digital infrastructure includes the proprietary G-HUB portal for sample tracking and project management.

Differentiator

Problem solved

Functional benefit

Products and services

• Central Lab Services Comprehensive central laboratory services providing diagnostic, medical examination, and pathological testing across over 5,000 efficacy and safety test items for clinical trial sponsors, covering general tests to specialized molecular genetic tests under GCLP certification.
• Bioanalytical Laboratory Services Bioanalytical services providing method development and validation, PK/PD analysis, biomarker analysis, and immunogenicity testing (ADA, NAb) for early and late-phase clinical trials, using specialized platforms including ELISA, MSD, Luminex, FACS, ddPCR, LC-MS/MS, and ELISpot.
• Clinical Support Services Quality management of the entire process from analysis consultation to data management for efficient clinical trial execution, including customized research support service for each project.
• Sample Management and Bio Logistics End-to-end sample management services including PBMC isolation, customized sample preparation, biobanking with multi-temperature preservation (Room Temperature, Refrigerated, -20°C, -70°C, -150°C LN2), real-time temperature monitoring with alarm systems, and overseas transportation via global logistics partners.
• Custom Lab Kit Production Customized lab kit production service for each project, supplying lab kits tailored for sample analysis at each subject visit, operated through a specialized lab kit production facility.
• R&D Laboratory Services Research and development services including method development and validation, translational research, biomarker discovery, and exploratory clinical sample testing and new technology evaluation.
• Data Management Services Clinical trial data management services including establishment of project-specific computer systems, web page-based result reporting, EDC upload through validated systems, and project management through the G-HUB portal.
• G-HUB Portal Proprietary specimen management platform and client portal enabling real-time sample tracking, temperature monitoring, location tracking, alerts, and barcode-based sample receipt-to-storage traceability, with AI-powered SOP search functionality for rapid client and regulatory audit responses.
• Clinical Consulting Services Clinical consulting services including PK analysis consulting and method development and validation advisory support for clinical trial sponsors.

Quantifiable outcome

• GCCL handles over 5,000 efficacy and safety test items across its Central Lab
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• GemPharmatech USminorStrategic or Co-development Partner · 22 June 2026New partnership established during BIO USA 2026 local partner visits. Discussions focused on potential collaboration across nonclinical and clinical development, connecting both companies' strengths to support global clients and explore joint business opportunities.
• Artiva TherapeuticsminorStrategic or Co-development Partner · 22 June 2026Partnership meeting held during BIO USA 2026 to gain insight into Artiva's development status and explore how GCCL's clinical trial sample analysis services could contribute to their global clinical development pipeline, particularly in cell therapy.
• VisMederi (Italy)coreStrategic or Co-development Partner · 30 March 2026MOU signed at World Vaccine Congress 2026 in Washington D.C. for vaccine development research collaboration. The agreement covers: joint projects for vaccine candidates targeting high-risk pathogens; research on infectious diseases and pandemic response; joint marketing and operational support. The partnership leverages both companies' BL2/BL3 research facilities and analytical capabilities to expand support for global vaccine development.
• KIMCo Foundation (Korea Innovative Medicines Consortium)coreStrategic or Co-development Partner · 24 February 2026MOU signed February 24, 2026, to support clinical research and regulatory readiness for early-stage biotech ventures invested in and fostered by KIMCo. Collaboration covers: company building support for KIMCo-invested bio ventures; national R&D projects and joint research; educational program planning and operation; joint marketing activities; and network/infrastructure sharing. Includes joint biomarker discovery, customized assay development, clinical design consulting, and IND regulatory consulting for biotech companies.
• Medicover Integrated Clinical Services (MICS)coreStrategic or Co-development Partner · 10 February 2026MOU signed February 10, 2026, to collaborate on multinational clinical trial services across Europe, U.S., and APAC. Key areas include: clinical trial operations and sample analysis collaboration across regions; project management support and coordinated client communication; joint marketing and client development; test item alignment and improved analytical efficiency. MICS contributes its experience and network in Europe and U.S. while GCCL provides specialized analytical capabilities and project management in APAC.
• OPIS (Optimed Integrated Services)coreStrategic or Co-development Partner · 14 January 2026MOU signed January 14, 2026, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, to expand collaboration and strengthen position in global clinical trial market. Areas include: joint global clinical trial services; conducting joint projects; developing new business opportunities. OPIS brings its Europe-focused global network and 26 years of CRO experience across 18 countries; GCCL contributes clinical trial analysis expertise in Asia.
• CLEVERcns (Seoul National University Research Center for Neuro-Psychiatric Disorder)coreStrategic or Co-development Partner · 19 September 2025MOU signed September 19, 2025, to advance clinical research in neuropsychiatric disorders. Collaboration areas include: strengthening preclinical-to-clinical linkages in brain disease research; joint development of CNS disease biomarkers and analytical methods; collaborative educational programs; end-to-end CNS project support and global expansion cooperation; and sharing domestic and international networks and resources. GCCL provides analytical platforms and services while CLEVERcns provides clinical research infrastructure and efficacy evaluation services.
• KoNECT (Korea National Enterprise for Clinical Trials)coreStrategic or Co-development Partner · 29 July 2025MOU signed on July 29, 2025, to foster mutual collaboration in clinical research. Key areas include: establishing institutional frameworks to strengthen clinical sample analysis capabilities; sharing medical and clinical insights; co-developing training and educational programs; collaborating on domestic and international promotion through each organization's networks; and exploring additional areas of mutual interest. This strategic collaboration links a government-backed clinical trial support institution with Korea's leading central lab.
• KoreaBIO/KOTRA (Korea Pavilion at BIO USA)coreGTM or Marketing Partner · 1 January 2025GCCL participated as part of the Korea Pavilion organized by KoreaBIO and KOTRA at BIO International Convention 2026 in San Diego, operating an exhibition booth at Booth 3735. This partnership provides GCCL with a formalized platform for international visibility and partnering within Korea's national biotech delegation.
• KoNECT (Korea Pavilion at ASCO/BIO)coreGTM or Marketing PartnerGCCL participated in KoNECT-organized Korea Pavilions at ASCO 2026 (Booth #12019, South Building Hall A) and BIO International 2026 (Booth 3735) to connect with global pharmaceutical, biotech, CRO, and research organizations. KoNECT organizes and coordinates the Korean national exhibition presence at major international bio conferences.

Scale indicators7 records

Recent moves3 records

Expansion highlights6 records

Direct peers

• ACM Global Central Laboratory: ACM Global is a pure-play central laboratory providing clinical trial sample analysis with global reach, particularly strong in oncology and infectious disease. It is a closely comparable mid-sized central lab peer with similar specialty focus areas.
• Eurofins Central Laboratory: Eurofins Central Laboratory provides global clinical trial central lab services with locations in the U.S., Europe, and Asia. It is a comparable peer in core central lab operations with similar multi-region positioning, though with broader geographic footprint.
• Seoul Clinical Laboratories (SCL): SCL is a major Korean clinical diagnostics laboratory and provides clinical trial central lab services to Korean pharma. It is a direct domestic competitor to GCCL in Korea's central lab market and competes for the same Korean clinical trial sponsorship.
• Wuxi AppTec (WuXi STA / WuXi Clinical): Wuxi AppTec provides bioanalytical and central lab services in Asia for global pharma and biotech, with deep capabilities in PK/PD, biomarker analysis, and small/large molecule bioanalysis. As an Asian-headquartered CRO with global reach, it is the most direct regional peer to GCCL.

Broad incumbents

• Labcorp Drug Development (Fortrea): Fortrea (spun off from Labcorp in 2023) is one of the world's largest central lab and clinical trial services providers, serving global pharma with multi-region lab capabilities. Both companies provide central lab and bioanalytical services for clinical trials, though Fortrea operates at vastly greater scale.
• ICON (formerly PRA Health Sciences): ICON Central Laboratories provides global central lab and bioanalytical services for clinical trials across therapeutic areas including oncology and infectious disease. It is a primary competitor for global sponsor central lab RFPs that GCCL targets through its MICS partnership.
• IQVIA Laboratories: IQVIA's central lab division provides global clinical trial sample analysis, bioanalytical services, and integrated eClinical platforms. It is a direct competitor for multinational trial central lab contracts and represents the scale benchmark GCCL aspires to challenge in APAC.
• Charles River Laboratories: Charles River provides bioanalytical, safety, and central lab services for clinical trials, with growing cell and gene therapy capabilities. It competes for bioanalytical and specialty testing work in oncology, biosimilars, and novel modalities where GCCL is also focused.
• SGS Health & Nutrition (Clinical Research): SGS operates a global clinical research business including central lab and bioanalytical services for pharma and biotech trials. It is a comparable peer in central lab operations with broader testing services portfolio and global geographic footprint.

Regional players

• GC Labs (Green Cross Medical Foundation): GC Labs is the clinical diagnostics arm of the Green Cross Medical Foundation (related entity to GCCL's parent GC Group) with 40 years of diagnostic experience. While primarily a clinical diagnostics lab, it provides overlapping sample analysis capabilities and is the in-group counterpart to GCCL's clinical trial focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@GlobalClinicalCentralLab
• LinkedInlinkedin.com/company/global-clinical-central-lab

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GCCL(Global Clinical Central Lab)